Impact of Nicotinamide Riboside (NR) on Kidney Function in Patients Undergoing Cardiac Surgery

NANot yet recruitingINTERVENTIONAL
Enrollment

100

Participants

Timeline

Start Date

July 24, 2024

Primary Completion Date

July 31, 2025

Study Completion Date

July 24, 2026

Conditions
Acute Kidney InjuryCardiac Valve Disease
Interventions
DIETARY_SUPPLEMENT

Nicotinamide riboside

"We will recruit the participant 24 hrs prior intervention, once the participant decides to enroll, we will administer by oral intake the supplement or placebo due to the result at randomizer.org.~The first NAD Riboside arm will be administered by oral intake with 2000 mg at enrollment, then we will administer 3000mg prior undergoing surgery with NG tube, 3000mg 12 hrs post-surgery with NG tube and 2000mg by oral intake 24 hrs after intervention. All the administrations with NG tube will be flushed with 0.9% saline solution."

OTHER

Placebo

"We will recruit the participant 24 hrs prior intervention, once the participant decides to enroll, we will administer by oral intake the supplement or placebo due to the result at randomizer.org.~The first dose of placebo arm will be administered by oral intake with 2000 mg at enrollment, then we will administer 3000mg prior undergoing surgery with NG tube, 3000mg 12 hrs post-surgery with NG tube and 2000mg by oral intake 24 hrs after intervention. All the administrations with NG tube will be flushed with 0.9% saline solution."

Trial Locations (1)

14080

Insituto Nacional de Cardiología Ignacio Chávez, México

All Listed Sponsors
lead

Instituto Nacional de Cardiologia Ignacio Chavez

OTHER

NCT06521307 - Impact of Nicotinamide Riboside (NR) on Kidney Function in Patients Undergoing Cardiac Surgery | Biotech Hunter | Biotech Hunter